Elsevier

Journal of Affective Disorders

Volume 240, November 2018, Pages 88-98
Journal of Affective Disorders

Research paper
Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study

https://doi.org/10.1016/j.jad.2018.07.040Get rights and content

Highlights

  • We searched for exosomes-related blood biomarkers by peripheral blood.

  • We normalized the neuron-related blood biomarkers by CD81 (neuron-derived exosomes).

  • Higher IL34/CD81 was the diagnostic biomarker for MDD.

  • Synaptophysin (SYP) and SYP/CD81 were positively correlated with severities of depression.

  • TNFR1/CD81 was positively correlated with “behavioral” symptoms including agitation.

Abstract

Background

Neuroinflammation is suggested to be a crucial factor in the pathophysiology of major depressive disorder (MDD). Analysis of neuron-derived exosomes (NDE) in peripheral blood has recently been highlighted to reveal the pathophysiology of brain diseases without using brain biopsy. Currently, human NDE studies require a considerable amount of peripheral blood to measure multiple substances inside exosomes. Previously, NDE-based clinical studies focusing on MDD have not been reported.

Methods

As an exploratory pilot case-control study between healthy controls (HC) and drug-free MDD patients (each; N = 34), we searched for NDE-related blood biomarkers with a small amount of peripheral blood using a novel sandwich immunoassay between anti-neuron antibody and antibodies against CD81 (an exosome marker) and against other proteins related to neuroinflammation and synaptic functions.

Results

Most neuron-related blood biomarkers had moderately to strongly positive correlation with CD81 (NDE), thus we normalized the above biomarkers by CD81 (quantity of each biomarker/CD81) to predict NDE-related blood substances. Interleukin 34 (IL34)/CD81 levels were significantly higher in MDD group compared to HC group. Synaptophysin (SYP), SYP/CD81, and tumor necrosis factor receptor 1 (TNFR1)/CD81 were positively correlated with severities of depression and/or various sub-symptoms.

Limitations

We did not actually extract NDE from peripheral blood.

Conclusions

Using a small amount of peripheral blood, we have successfully detected possible NDE-related blood biomarkers. This is the first study to suggest that not only SYP and TNFR1 but also IL34 are important blood biomarkers for patients with MDD. Further studies are warranted to evaluate the present study.

Introduction

Major depressive disorder (MDD) is a common psychiatric disorder. The prevalence of MDD is considered to be 4.7% worldwide, and its burden is extremely large (DALYs and Collaborators, 2017, Ferrari et al., 2013). However, MDD diagnosis and symptom evaluation have depended on subjective information such as physician's clinical experiences and patient's self-assessments, which can unfortunately lead to misdiagnoses (Mitchell et al., 2009). Such difficulties have caused confusion in clinical practice of MDD (Kato et al., 2016, Kato and Kanba, 2017, Kato et al., 2011b, 2011c). Thus, to resolve the limitations in clinical practice of MDD, the need for biological biomarkers in the objective clinical evaluation of MDD has increased.

Previous research has revealed that neuroinflammation is very important in the pathophysiology of MDD, and that inflammatory processes may be involved with at least some of neurodegeneration in MDD (Dantzer et al., 2008, Goldsmith et al., 2016, Maes et al., 2009). Inflammatory cytokines and their receptors such as interleukin (IL) 1β, IL6, IL34, tumor necrosis factor (TNF) α, and TNF receptor 1 (TNFR1) are known to be associated with neuroinflammation linked to MDD (Chitu et al., 2016, Dowlati et al., 2010, Goldsmith et al., 2016, Grassi-Oliveira et al., 2009). In addition, postmortem brain studies in patients with depression and rodents with depression model have reported altered levels of synaptophysin (SYP), one of the synaptic vesicle phosphoproteins reflecting synaptic functions and density (Gilabert-Juan et al., 2012, Greengard et al., 1993, Liu et al., 2015). Such studies have suggested synaptic dysfunction in MDD, and portions of synaptic dysfunction may be caused by inflammatory cytokines (Sofroniew, 2014, Vezzani and Viviani, 2015). On the other hand, the orexin neuronal system has been shown to play important roles in the regulation of sleep/wakefulness, feeding behavior, reward system, and emotion, which are often disturbed in depression (Abbas et al., 2015, Chieffi et al., 2017, Sakurai, 2014, Soya et al., 2017). Orexin acts on orexin receptors (OXR), orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Interestingly, the orexin neuronal system has been also reported to modulate synaptic functions, and closely related to monoaminergic neurons (Chieffi et al., 2017, Sakurai, 2014). Therefore, the orexin neuronal system may be involved in the pathophysiology of MDD (Abbas et al., 2015, Chieffi et al., 2017, Nollet and Leman, 2013, Sakurai, 2014). Based on such evidence, we have hypothesized that the above proteins (related to neuroinflammation and synaptic functions), which are more or less carried from neurons in the brain into peripheral blood via exosomes, may be useful biomarkers for MDD (Brites and Fernandes, 2015, Chieffi et al., 2017, Greengard et al., 1993, He et al., 2015, Kandere-Grzybowska et al., 2003, Murray et al., 2015, Ogoshi et al., 2005, Ohgidani et al., 2014, Qu et al., 2007, Reinhardt et al., 2013, Sakurai, 2014, Sallmann et al., 2000, Stellwagen et al., 2005).

Various research methods including peripheral blood tests have been utilized in biomarker studies of MDD. Cerebrospinal fluid (CSF) analysis and brain imaging/brain physiological examination such as magnetic resonance imaging and electroencephalogram are known as biomarker research methods directly reflecting brain pathophysiology (Gadad et al., 2017, Gong and He, 2015, Gururajan et al., 2016, Kunugi et al., 2015). CSF-based biomarkers are invasive and brain imaging/brain physiological examination-based biomarkers are expensive and unsuitable for analysis of molecular dynamics, limiting their appeal to both patients and physicians (Mustapic et al., 2017). In contrast, a peripheral blood test can be carried out easily, quickly, and widely not only in research institutes but also primary care settings. However, peripheral blood test-based biomarkers are not necessarily expressive of molecular dynamics in the brain, since the brain and peripheral blood are strictly separated by the blood-brain barrier (Raison et al., 2010).

Recently, exosomes obtained from peripheral blood have attracted attention in various fields ranging from mechanism studies aimed at understanding the pathophysiology of various diseases such as cancers and neurodegenerative diseases to drug discovery research (Brites and Fernandes, 2015, Goh et al., 2017, Levy, 2017, Luarte et al., 2017, Mitsuhashi et al., 2013, Muller et al., 2016, Sarko and McKinney, 2017, Tavakolizadeh et al., 2017, Tsilioni et al., 2014). Exosomes are approximately 100 nm extracellular vesicles with lipid bilayer membranes, considered to be secreted from most cell types including neurons (Raposo and Stoorvogel, 2013, Yanez-Mo et al., 2015). Exosomes have been recognized as potent vehicles of intercellular communication, due to their capacity to transfer proteins, lipids, and RNA (Raposo and Stoorvogel, 2013, Yanez-Mo et al., 2015). Moreover, recent studies have reported that the composition of exosomes is different depending on cell types, states, and environments (Beninson and Fleshner, 2014, de Jong et al., 2012). In addition, since exosomes can cross the blood-brain barrier from both directions, circulating exosomes in blood are expected to reveal the pathophysiology of brain diseases without using brain biopsy and CSF analysis (Mustapic et al., 2017). Thus, peripheral blood biomarker studies of brain diseases have utilized exosomes so as to overcome the above-mentioned drawbacks of peripheral blood tests, and recent studies have reported several methods to extract neuron-derived exosomes (NDE) from peripheral blood (Fiandaca et al., 2015, Goetzl et al., 2015, Mustapic et al., 2017). On the other hand, one of the most crucial issues in current human NDE studies is that a considerable amount of peripheral blood (at least 500 µL/each patient) is required to extract exosomes, which is a limitation in measuring multiple substances contained in the NDE (Mustapic et al., 2017). Exosomes have recently been suggested to be promising in the evaluation, diagnosis, and treatment of depression, however, to our knowledge, NDE-based clinical studies focusing on depression and in particular MDD have not been reported until now (Brites and Fernandes, 2015, Tavakolizadeh et al., 2017). We have hypothesized that if blood proteins of interest are positively correlated with NDE, these proteins likely come from NDE. We have proposed that measuring the levels of neuron-related blood biomarkers normalized by the levels of NDE (quantity of each biomarker/NDE) in patients with brain diseases including MDD may be useful to predict altered levels of substances contained in the NDE without actually extracting NDE. Just recently, using a small amount of peripheral blood (less than 50 µL/each patient), we have established a novel sandwich immunoassay between anti-neuron antibody (synaptosome associated protein 25 (SNAP25), a neuronal protein involved in the fusion of small synaptic vesicles with the presynaptic plasma membrane (Sadoul et al., 1995)) and antibodies against CD81 (one of the typical markers of exosomes) and against other targeting proteins (Fig. 1) (Kawata et al., 2018). Using this method, we have revealed that the levels of neuron-related blood targeting proteins normalized by the levels of CD81 (NDE) are significantly associated with the clinical concussion prognosis and recovery process in patients with sport-related neurotrauma (Kawata et al., 2018).

Based on the above-introduced hypothesis of depression, we have suggested that some proteins related to neuroinflammation and synaptic functions may be carried from neurons in the brain into peripheral blood via exosomes during the clinical course of depression, and that measuring such neuron-related blood proteins normalized by CD81 (NDE) may be useful for the objective clinical evaluation of MDD. Thus, as an exploratory pilot case-control study between healthy controls (HC) and drug-free MDD patients, we herein searched for NDE-related blood biomarkers using the above sandwich immunoassay with a small amount of peripheral blood (less than 50 µL/each patient).

Section snippets

Methods

The present study was approved by the ethics committee of Kyushu University and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Results

Demographics and clinical variables were described in Table 1. Drug-free MDD patients (N = 34) were in acute episode of MDD (disease duration: 4.0 (4.0) weeks). SOD of most patients was between moderate to severe in accordance with BDI-II total score (29.9 ± 11.1). There were no significant differences in sex and age between HC and MDD group.

Discussion

The present exploratory pilot study suggests, for the first time, the clinical utility of neuron-related blood biomarkers normalized by CD81 (NDE) in drug-free MDD patients, using a novel ELISA method with a small amount of peripheral blood. First, this study has shown that most neuron-related blood biomarkers including IL34 and TNFR1 have moderately to strongly positive correlation with CD81 (NDE). Based on such significant correlation between neuron-related blood biomarkers and CD81, we

Limitations

The present exploratory pilot study has some limitations. First, we did not actually extract NDE from peripheral blood to measure the biomarkers contained in the NDE. It is important to note that one of the most crucial problems in current human NDE studies is that a considerable amount of peripheral blood is required to extract exosomes from peripheral blood and to measure multiple substances contained in the NDE. Fortunately, using a small amount of peripheral blood, we herein successfully

Conclusions

In the present blood biomarker study, we have shown the clinical utility of neuron-related blood biomarkers normalized by CD81 (NDE) in drug-free MDD patients, using a novel ELISA method with a small amount of peripheral blood. The present study has highlighted the important interactions between neuroinflammation, neuronal damage, and synaptic dysfunction possibly associated with inflammatory cytokines in the pathophysiology of MDD at least during the acute phase. Diagnosis and symptoms

Conflicts of interest statement

All the authors have declared that no conflicts of interest exist.

Role of funding source

This work was partially supported by Grant-in-Aid for Scientific Research on (1) Innovative Areas “Will-Dynamics” and "Glia Assembly" of The Ministry of Education, Culture, Sports, Science, and Technology, Japan (JP16H06403 to T.A.K.; JP25117011 to S.K.), (2) The Japan Agency for Medical Research and Development (AMED). (Syogaisya-Taisaku-Sogo-Kenkyu-Kaihatsu-Jigyo to T.A.K. & S.K. (JP17dk0307047, & JP18dk0307075), and Yugo-No to T.A.K. (JP18dm0107095)), (3) KAKENHI - the Japan Society for the

Contributors

T.A.K., M.M., and N.K. contributed to the conception and design.

T.A.K. was responsible for protocol of the study.

N.K., T.A.K., M.M., M.S-K., N.Sh., K.H., M.O., N.Sa., and H.K. contributed to the investigation.

N.K., T.A.K., and M.M. contributed to the data checking, analysis, and interpretation of data.

N.K. and T.A.K. drafted the article, and T.S. and S.K. revised it critically for important intellectual content.

All the authors provided final approval of the version to be published.

Acknowledgments

The authors would like to thank Dr. Koji Tanaka, Dr. Junji Kishimoto, Mr. Keita Kurahara, Ms. Ryoko Katsuki, Ms. Sakumi Kakimoto, and Ms. Yoko Zushi for their research support and/or assistance.

References (93)

  • K. Hayakawa et al.

    Minocycline, a microglial inhibitor, diminishes terminal patients' delirium?

    Am. J. Geriatr. Psychiatry

    (2014)
  • H. Horikawa et al.

    Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2010)
  • T.A. Kato et al.

    Introducing the concept of modern depression in Japan; an international case vignette survey

    J. Affect. Disord.

    (2011)
  • T.A. Kato et al.

    Are Japan's hikikomori and depression in young people spreading abroad?

    Lancet

    (2011)
  • N. Kuwano et al.

    Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naive patients with major depressive disorder: an exploratory pilot case-control study

    J. Affect. Disord.

    (2018)
  • A.J. Mitchell et al.

    Clinical diagnosis of depression in primary care: a meta-analysis

    Lancet

    (2009)
  • T. Mizuno et al.

    Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-beta neurotoxicity

    Am. J. Pathol.

    (2011)
  • F. Ogoshi et al.

    Tumor necrosis-factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels in a subset of hippocampal pyramidal neurons

    Exp. Neurol.

    (2005)
  • T.A. Reinhardt et al.

    Bovine milk proteome: quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from Staphylococcus aureus mastitis

    J. Proteomics

    (2013)
  • M. Sato-Kasai et al.

    Aripiprazole inhibits polyI:C-induced microglial activation possibly via TRPM7

    Schizophr. Res.

    (2016)
  • E. Setiawan et al.

    Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study

    Lancet Psychiatry

    (2018)
  • I. Tsilioni et al.

    Exosomes in neurologic and psychiatric disorders

    Clin. Ther.

    (2014)
  • A. Vezzani et al.

    Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability

    Neuropharmacology

    (2015)
  • J.F. Weinberger et al.

    Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation

    Brain. Behav. Immun.

    (2015)
  • R. Yirmiya et al.

    Depression as a microglial disease

    Trends Neurosci.

    (2015)
  • M.G. Abbas et al.

    Comprehensive behavioral analysis of male Ox1r (-/-) mice showed implication of orexin receptor-1 in mood, anxiety, and social behavior

    Front. Behav. Neurosci.

    (2015)
  • D.H. Arendt et al.

    Depressive behavior and activation of the orexin/hypocretin system

    Behav. Neurosci.

    (2013)
  • H. Bading

    Nuclear calcium signalling in the regulation of brain function

    Nat. Rev. Neurosci.

    (2013)
  • A.T. Beck et al.

    Manual for Beck Depression Inventory

    (1996)
  • D. Brites et al.

    Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation

    Front. Cell. Neurosci.

    (2015)
  • S. Chieffi et al.

    Orexin system: the key for a healthy life

    Front. Physiol.

    (2017)
  • A. Coppen

    The biochemistry of affective disorders

    Br. J. Psychiatry

    (1967)
  • G.B.D. DALYs et al.

    Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

    Lancet

    (2017)
  • R. Dantzer et al.

    From inflammation to sickness and depression: when the immune system subjugates the brain

    Nat. Rev. Neurosci.

    (2008)
  • O.G. de Jong et al.

    Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes

    J. Extracell. Vesicles

    (2012)
  • A.J. Ferrari et al.

    Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature

    Psychol. Med.

    (2013)
  • M.S. Fiandaca et al.

    Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study

    Alzheimers Dement.

    (2015)
  • M.B. First et al.

    Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)

    (2002)
  • T.E. Fitch et al.

    LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy

    Front. Neurosci.

    (2014)
  • B.S. Gadad et al.

    Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks

    J. Affect. Disord.

    (2017)
  • E.J. Goetzl et al.

    Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

    Neurology

    (2015)
  • E.J. Goetzl et al.

    Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease

    FASEB J.

    (2016)
  • W.J. Goh et al.

    Bioinspired cell-derived nanovesicles versus exosomes as drug delivery systems: a cost-effective alternative

    Sci. Rep.

    (2017)
  • D.R. Goldsmith et al.

    A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

    Mol. Psychiatry

    (2016)
  • R. Grassi-Oliveira et al.

    Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder

    Psychiatry Clin. Neurosci.

    (2009)
  • P. Greengard et al.

    Synaptic vesicle phosphoproteins and regulation of synaptic function

    Science

    (1993)
  • Cited by (38)

    • Tiny in size, big in impact: Extracellular vesicles as modulators of mood, anxiety and neurodevelopmental disorders

      2022, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      These EVs contained astrocyte-specific markers, indicating they were brain-derived (Gómez-Molina et al., 2018). When screening the blood for inflammatory markers in neuron-derived exosomes, Kuwano and colleagues preliminarily reported that synaptophysin (SYP), TNF receptor 1 (TNFR1) and IL-34 were positively correlated with severity of depression symptoms indicating vesicle cargo in the periphery are sensitive markers of stress-related depression (Kuwano et al., 2018). The aforementioned studies highlight that EVs may trigger MDD via modulation of neuroinflammation.

    • Potential approaches and recent advances in biomarker discovery in autism spectrum disorders

      2022, Neural Engineering Techniques for Autism Spectrum Disorder: Volume 2: Diagnosis and Clinical Analysis
    • Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder

      2021, Psychiatry Research
      Citation Excerpt :

      There is also evidence that supports that MPO enzyme coding gene and MPO expression are important for cognitive regulation (Talarowska et al., 2015). Despite the fact that a range of researches have studied the role of inflammatory cytokines in MDD, the detection methods are inconsistent (Chen et al.,2017; Kuwano et al., 2018). Heterogeneity of MDD, comorbidity of mental disorders, and medication may all increase the difficulty of the study and may lead to conflicting results (Shariq et al., 2018).

    • BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment

      2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      Thus, peripheral exosomes from depressed subjects injected into mice can induce depressive-like behaviors in mice via the regulation of neurogenesis (Wei et al., 2020). Several inflammatory biomarkers of neuronal inflammation have been shown to be higher in neuron-derived exosomes from total blood cells of drug-free MD subjects than those from controls (Kuwano et al., 2018). Interestingly, the levels of sortilin, a molecule that participates in the transfer of exosomes (Wilson et al., 2014), is altered in the serum of MD subjects (Buttenschøn et al., 2018; Devader et al., 2017; Mazella et al., 2019), and the levels of its pro-peptide increases upon treatment with electroconvulsive therapy (Roulot et al., 2018).

    View all citing articles on Scopus
    View full text